Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 522

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 522
---
 in consolidated net income are depreciation and amortization, stock based compensation, interest expense and the provision for income taxes. Recently Issued Accounting Pronouncements In November 2024, the FASB issued Accounting Standards Update No. 2024 -03, Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Topic 220): Disaggregation of Income Statement Expenses (“ASU 2024 -03”). ASU 2024 -03requires additional disclosure of certain amounts included in the expense captions presented on the condensed consolidated statement of operations as well as disclosures about selling expenses. The ASU is effective on a prospective basis, with the option for retrospective application, for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted for annual financial statements that have not yet been issued. The Company is currently evaluating the impact of ASU 2024 -03on its condensed consolidated financial statements and related disclosures. There are no other recently issued accounting pronouncements that the Company believes might have a material impact on its financial position or results of operations. F-62

DIAMIR BIOSCIENCES CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 — PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consist of the following:

|                                    |     |   | May 31, 
    2025 |     |   | May 31, 
    2024 |
|:-----------------------------------|:----|:--|--------:|:----|:--|--------:|
| Deferred costs of equity financing |     | $ |       — |     | $ | 114,000 |
| Advances to suppliers              |     |   |  45,252 |     |   |       — |
| Other                              |     |   |   1,397 |     |   |   6,139 |
| Total                              |     | $ |  46,649 |     | $ | 120,139 |

NOTE 5 — INTANGIBLE ASSETS In the Company’s fiscal year ended May 31, 2021, the Company acquired laboratory assets and operations, including the laboratory’s CLIA certification and its state operating licenses from a provider of molecular diagnostic tests. The Company allocated $ 197,761of the total purchase price to the certification and licenses, which it considers indefinite -livedintangible assets.

NOTE